• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ASCO: Merck KGaA, Pfizer's Bavencio combo misses survival mark in crowded kidney...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 23, 2024 at 10:22: PM
via Five years after scoring an FDA approval to treat newly diagnosed advanced kidney cancer, the combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta has failed on the overall survival endpoint of a phase 3 trial.

article source
 

<



Similar threads

cafead
ASCO: Pfizer, Merck KGaA&#039;s Bavencio posts win in rare gynecological cancer
Replies
0
Views
194
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASCO: Merck&#039;s Keytruda trips in EGFR lung cancer as Roche&#039;s Tecentriq fails in...
Replies
0
Views
152
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASCO: Merck bills Keytruda, used around surgery, as new standard in &#039;messy&#039; early...
Replies
0
Views
213
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA...
Replies
0
Views
167
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASCO preview: Merck&#039;s Keytruda, Novartis&#039; Kisqali face their moment of truth in...
Replies
0
Views
217
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote